Resilience, a CDMO of biologic drug substances and drug products, has expanded its strategic partnership with Eli Lilly and Company to increase US production with new manufacturing investments in Ohio. Building on a partnership first established in 2023, a $750-million investment by Resilience and Lilly has expanded Resilience’s advanced manufacturing operations in the Cincinnati region, which will now include Lilly’s KwikPen injectable device for innovative medicines for treating diabetes and obesity. The addition of KwikPen production will create at least 400 new skilled jobs, bringing total Resilience-created jobs in Ohio to more than 1,400 across its facilities. Site preparation for the campus expansion is underway, with full operations expected to commence in early 2027. 

The multi-year manufacturing partnership between Lilly and Resilience has produced more than 150 million doses of medicines in vial and prefilled syringe formats. Resilience currently operates two advanced facilities in the Cincinnati region that together comprise nearly 1 million square feet and employ nearly 1,000 employes across manufacturing, operations, quality, and regulatory functions. The company recently announced the establishment of its global headquarters in Blue Ash, Ohio. 

Source: Resilience